KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Capital Expenditures (2016 - 2025)

Boston Scientific's Capital Expenditures history spans 17 years, with the latest figure at $351.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 26.71% year-over-year to $351.0 million; the TTM value through Dec 2025 reached $876.0 million, up 10.89%, while the annual FY2025 figure was $876.0 million, 10.89% up from the prior year.
  • Capital Expenditures for Q4 2025 was $351.0 million at Boston Scientific, up from $181.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $351.0 million in Q4 2025 and bottomed at $75.0 million in Q1 2021.
  • The 5-year median for Capital Expenditures is $168.0 million (2024), against an average of $176.0 million.
  • The largest YoY upside for Capital Expenditures was 118.37% in 2021 against a maximum downside of 25.0% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $266.0 million in 2021, then dropped by 20.3% to $212.0 million in 2022, then increased by 25.94% to $267.0 million in 2023, then rose by 3.75% to $277.0 million in 2024, then grew by 26.71% to $351.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Capital Expenditures are $351.0 million (Q4 2025), $181.0 million (Q3 2025), and $157.0 million (Q2 2025).